Home Newsfeeds HC Wainwright & Co. Maintains Buy on Deciphera Pharmaceuticals, Raises Price Target to $20

HC Wainwright & Co. Maintains Buy on Deciphera Pharmaceuticals, Raises Price Target to $20

HC Wainwright & Co. analyst Andrew Fein maintains Deciphera Pharmaceuticals (NASDAQ:DCPH) with a Buy and raises the price target from $15 to $20.

byBenzinga Newsdesk

August 5, 2022

1 minute read

HC Wainwright & Co. analyst Andrew Fein maintains Deciphera Pharmaceuticals (NASDAQ:DCPH) with a Buy and raises the price target from $15 to $20.

Binance Reportedly Moves $3.9B In Tether Ahead Of Major DOJ Settlement

By Mehab Qureshi

November 23, 12:30 AM

Cryptocurrency exchange Binance has moved $3.9 billion in Tether (CRYPTO: USDT) from its cold wallet just before settling with the Department of Justice (DOJ).

$USDT

Leap Therapeutics To Present Updated Data From Part A Of The DisTinGuish Study Of DKN-01 Plus Tislelizumab And Chemotherapy In Gastric Cancer Patients At The 2023 ASCO Annual Meeting

By Happy Mohamed

April 27, 6:57 AM

Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that the Company will be presenting new long-term follow-up data

LPTX

Zero-Fees Ethereum (ETH) Trading Coming On Binance This Week

By Samyuktha Sriram

August 24, 3:46 AM

The world’s largest cryptocurrency exchange Binance is launching zero-fees trading for Ethereum (CRYPTO: ETH) on its platform. What Happened: Binance said that the zero fees trading option for ETH would go live on Friday.

$BUSD